ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Apr 2024 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

15 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

12 Apr 2024 15:22:53 By Nasdaq GlobeNewswire

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

12 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

22 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in March

27 Feb 2024 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

23 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

15 Feb 2024 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

08 Feb 2024 15:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

06 Feb 2024 07:00:01 By Nasdaq GlobeNewswire

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome

05 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

25 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Jan 2024 15:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

07 Jan 2024 10:00:00 By Nasdaq GlobeNewswire

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

04 Jan 2024 07:00:29 By Nasdaq GlobeNewswire

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 Dec 2023 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

18 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in November

20 Nov 2023 15:30:00 By Nasdaq GlobeNewswire